^
    CANCER:

    Lung Non-Small Cell Squamous Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    pembrolizumab
    cemiplimab-rwlc
    		0
    PD1 inhibitor
    tislelizumab
    penpulimab
    sintilimab
    serplulimab
    nivolumab
    nivolumab + ipilimumab
    		1
    PD1 inhibitor, CTLA4 inhibitor
    pembrolizumab + MK-1308
    PSB205
    2
    PD-L1 inhibitor
    atezolizumab
    3
    VEGFR-2 inhibitor
    ramucirumab
    4
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    5
    Tubulin polymerization promoter, Bcl2 inhibitor, Tubulin inhibitor
    carboplatin + albumin-bound paclitaxel
    6
    DNA synthesis inhibitor
    gemcitabine
    EGFR inhibitor
    necitumumab
    		7
    EGFR inhibitor
    erlotinib
    osimertinib
    gefitinib
    8
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    9
    VEGF-A inhibitor
    bevacizumab
    10
    ALK inhibitor
    ALK inhibitor
    alectinib
    11
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    12
    PIK3CA inhibitor
    GDC-0032
    13
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    14
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    15
    HER3 antagonist, EGFR inhibitor
    cetuximab + HMBD-001
    infigratinib
    		16
    FGFR inhibitor
    ABSK091
    BAY 1163877
    PRN1371
    17
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    DP
    GemCarbo
    VC
    GemVin
    		18
    Chemotherapy
    GD
    CaT
    CP
    GC
    EP
    19
    Immunotherapy
    Immunotherapy
    20
    Immunotherapy, Angiogenesis inhibitor
    Immunotherapy + Angiogenesis inhibitor
    21
    Tyrosine kinase inhibitor, EGFR inhibitor
    EGFR inhibitor + Tyrosine kinase inhibitor
    22
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    23
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    24
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    carboplatin + docetaxel
    25
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    26
    c-MET-targeted antibody-drug conjugate, EGFR inhibitor, Microtubule inhibitor
    erlotinib + ABBV-399
    27
    ALK inhibitor, EGFR inhibitor
    brigatinib
    crizotinib + erlotinib
    28
    mTORC1 inhibitor, Glutaminase inhibitor, mTORC2 inhibitor
    CB-228 + CB-839
    29
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    30
    Bcr-abl tyrosine kinase inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    erlotinib + dasatinib
    31
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    32
    TGFβ inhibitor, EGFR inhibitor
    BCA101
    33
    Microtubule inhibitor, CD228-targeted antibody-drug conjugate
    SGN-CD228A
    34
    Multi-tyrosine kinase inhibitor
    anlotinib
    everolimus + adagrasib
    		35
    KRAS G12C inhibitor, mTOR inhibitor
    everolimus + sotorasib
    everolimus + ARS-1620
    36
    Mesothelin-targeted CAR-T immunotherapy
    MSLN-CAR-T cell therapy
    37
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    38
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    39
    Wnt signalling pathway inhibitor, TNIK inhibitor
    NCB-0846
    No biomarker
    EGFR wild-type
    EGFR mutation
    EGFR exon 20 insertion
    EGFR exon 19 deletion
    EGFR R1052K
    EGFR L861Q
    EGFR amplification
    EGFR L858R
    EGFR E746_S752delinsV
    EGFR G719C + EGFR S768I
    EGFR expression
    EGFR L858R + EGFR T790M
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    HER-2 Q57R
    HER-2 E395K
    ALK wild-type
    ALK positive
    ALK rearrangement
    ERBB4 G668V
    ROS1 wild-type
    NFE2L2 mutation
    EML4-ALK fusion
    EML4-ALK fusion + ALK G1202R
    NFE2L2 E79K
    FGFR1 amplification
    FGFR1 overexpression
    PIK3CA mutation + PTEN deletion
    DDR2 S768R
    KEAP1 mutation
    FGFR3-TACC3 fusion
    PIK3CA mutation
    MET positive
    SLC35A2 overexpression
    EGFR mutation + GRM8 mutation
    CCND1 amplification
    High 18-gene tumor inflammation signature score
    TNIK overexpression
    FGFR3 overexpression
    FGFR2 overexpression
    EGFR mutation + CREBBP mutation
    EGFR mutation + ZNF217 mutation
    MSLN positive
    NTRK1 fusion
    STK11 mutation
    MET exon 14 mutation + EGFR exon 20 insertion
    PD-L1 overexpression + HER-2 exon 20 insertion
    EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification
    KL overexpression
    EGFR wild-type + MET wild-type
    MELTF overexpression
    KRAS G12C